Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05208281
Other study ID # IDB-MPS-II-III
Secondary ID
Status Recruiting
Phase Phase 2/Phase 3
First received
Last updated
Start date November 30, 2021
Est. completion date March 2028

Study information

Verified date March 2024
Source AO GENERIUM
Contact Svetlana B. Korotkova, MD, PhD
Phone +7(495) 988 47 94
Email sbkorotkova@generium.ru
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is phase 2/3 study to evaluate the safety, pharmacokinetics, pharmacodynamics, and efficacy of the investigational product GNR-055 in MPS II (Hunter syndrome) patients of different age groups.


Description:

GNR-055 is intended for ERT in patient with Mucopolysaccharidosis type II (MPS II), or Hunter syndrome. MPS II is a recessive X-linked inheritance lysosomal storage disease, which is characterized by a deficiency of the lysosomal enzyme iduronate-2-sulfatase (ID2S), caused by a mutation in the ID2S gene. Enzyme deficiency leads to the accumulation of Glycosaminoglycans (GAG) (mainly of heparan and dermatan sulfates) in lysosomes of almost all types of cells of various tissues and organs. The disease is manifested by growth retardation, damage of many organs and systems, severe deformations of bones and joints, gross facial features, pathology of the respiratory and cardiovascular systems, damage to parenchymal organs (hepatosplenomegaly), and hearing impairment. A severe form of the disease occurs with the involvement of the nervous system in the pathological process, including mental retardation, behavior anomalies, and impaired motor function. GNR-055 is a recombinant modified ID2S capable to penetrate the blood-brain barrier and thus expected to prevent neurodegenerative consequences and the cognitive deficit and to attain a significant improvement in the life quality and expectancy of patients with MPS II. Study IDB-MPS-II-III is a multicenter, open-label, multi-cohort study to assess safety, PK and PD, and efficacy of GNR-055 in patients of different age groups with MPS II (Hunter syndrome).


Recruitment information / eligibility

Status Recruiting
Enrollment 32
Est. completion date March 2028
Est. primary completion date February 2025
Accepts healthy volunteers No
Gender Male
Age group N/A and older
Eligibility Inclusion Criteria: - Signed inform consent; - Verified diagnosis of MPS II (Hunter syndrome); - Naïve patients or patients who have received standard ERT whit idursulfase products; - No contraindications for lumbar puncture as judged by the Investigator; - Willingness and ability to follow study procedures. Exclusion Criteria: - Clinically pronounced hypersensitivity to ID2S or any other component of the drug product; - History of hematopoietic stem cell transplantation (HSCT) or bone marrow transplantation; - Implanted or external non-removable metal devices, a cardiac pacemaker, or other objects sensitive to the magnetic field that may pose a danger to both the wearer and the correct operation of magnetic resonance imaging (MRI) equipment; - Concomitant diseases and conditions that, in the Investigator's opinion, can put at risk the patient's safety during his/her participation in the study, or which will influence the safety data analysis in case of the disease/condition exacerbation during the study.

Study Design


Intervention

Drug:
GNR-055 1.0-2.0-3.0 mg/kg
Weekly IV infusion (lyophilized powder) 1.0-2.0-3.0 mg/kg
GNR-055 2.0 mg/kg
Weekly IV infusion (lyophilized powder) 2.0 mg/kg
GNR-055 3.0 mg/kg
Weekly IV infusion (lyophilized powder) 3.0 mg/kg

Locations

Country Name City State
Russian Federation State Autonomous Healthcare Institution of the Sverdlovsk Region Regional Children's Clinical Hospital Ekaterinburg
Russian Federation Federal State-Funded Healthcare Institution Central Clinical Hospital of the Russian Academy of Sciences (Research Institute of Pediatrics and Child Health Protection of the Central Clinical Hospital of the Russian Academy of Sciences) Moscow
Russian Federation V.I. Vernadsky Crimean Federal University Simferopol
Russian Federation Federal State Budgetary Educational Institution of Higher Education "St. Petersburg State Pediatric Medical University" of the Ministry of Health of the Russian Federation St. Petersburg
Russian Federation State Budgetary Healthcare Institution Republican Medical Genetic Center Ufa

Sponsors (1)

Lead Sponsor Collaborator
AO GENERIUM

Country where clinical trial is conducted

Russian Federation, 

Outcome

Type Measure Description Time frame Safety issue
Primary Incidence of Adverse events (AEs) and Serious Adverse Events (SAEs) Safety assessment will be performed based on the subjective complaints, physical examination, assessment of vital signs, laboratory tests, and 12-lead ECG; Incidence of allergic and infusion-related reactions; Incidence of Anti-Drug Antibodies (ADAs) against GNR-055 and their neutralizing activity. Baseline to Week 56
Primary Urine GAG excretion Changes in levels of urine GAG excretion after multiple-dose administration of GNR-055 Baseline to Week 4, 8, 10, 26, and 52
Secondary Serum concentration of the GNR-055 Assessment of the serum concentration of GNR-055 and calculation of Cmax, AUC, T1/2, Cl et other parameters after multiple-dose administration Week 52
Secondary GAG level in CerebroSpinal Fluid (CSF) Changes in levels of CSF GAG after multiple-dose administration of GNR-055 Baseline to Week 6, 10, 26, and 52
Secondary Serum GAG level Changes in levels of serum GAG after multiple-dose administration of GNR-055 Baseline to Week 4, 8, 10, 26, and 52
Secondary Large joint range of motion Changes over time in the large joint range of motion after multiple-dose administration of GNR-055 Week 8, 10, 26, and 52
Secondary Liver and spleen volumes (MRI) Changes over time in liver and spleen volume according to ultrasound/MRI after multiple-dose administration of GNR-055 Baseline to Week 8, 10, 26, and 52
Secondary 6-minute walk test Changes over time in the results of the 6-minute walk test after multiple-dose administration of GNR-055 Baseline to Week 8, 10, 26, and 52
Secondary Left ventricular mass by EchoCG Changes over time in the left ventricular mass according to Echocardiography (Echo-CG) after multiple-dose administration of GNR-055 Baseline to Week 8, 10, 26, and 52
Secondary Lung Forced Vital Capacity (FVC) Changes over time in FVC according to spirometry after multiple-dose administration of GNR-055 Baseline to Week 8, Week 26, and Week 52
Secondary Neurocognitive functions assessment Changes over time in neurocognitive functions after multiple-dose administration of GNR-055 Baseline to Week 12, 26, and 52
Secondary Brain white/gray matter structures (MRI) Changes over time in the quantitative MRI brain structure parameters after multiple-dose administration of GNR-055 Baseline to Week 26, and 52
Secondary Serum neuromarkers Changes in levels of serum neuromarkers after multiple-dose administration of GNR-055 Baseline to Week 24, and 52
Secondary CSF neuromarkers Changes in levels of CSF neuromarkers after multiple-dose administration of GNR-055 Baseline to Week 24, and 52
See also
  Status Clinical Trial Phase
Completed NCT02402985 - Comparison of a Plant Protein Diet to a Animal Protein Diet Emphasized in Type 2 Diabetics N/A
Completed NCT02380846 - The Metabolic Effects of Consuming Carbohydrate With Different Protein Types N/A
Not yet recruiting NCT01916603 - Diet, Physical Activity and Breastfeeding Intervention on Maternal Nutrition, Offspring Growth and Development N/A
Completed NCT01616082 - Effect of Caloric Restriction on Fat Oxidation in Obese Men and Women (Magellan II) N/A
Completed NCT01737164 - Effect of Age on Glucose and Lipid Metabolism N/A
Terminated NCT00935766 - Effect of Fish Oil (Omega-3 Fatty Acids) on Arteries Phase 3
Enrolling by invitation NCT00628199 - Study to Create Potential Cell-Based Therapies to Treat Human Disease and Disability
Recruiting NCT04958109 - Evaluation of Kisspeptin Glucose-Stimulated Insulin Secretion With Oral Glucose Tolerance Test Phase 1
Completed NCT02275429 - Metabolic Disorders in Ultramarathon Runners During and After the Reunion Island Madmen's Diagonal N/A
Completed NCT01968720 - Pilot Study To Assess CAT-2003 in Patients With Severe Hypertriglyceridemia Phase 2
Completed NCT01705782 - The Effects of Amino Acid Supplement During Acute Inflammation. N/A
Completed NCT01708681 - Lean Seafood Intake and Postprandial Metabolism N/A
Completed NCT01719913 - The Effect of Gluten on Gut Microbiome and Metabolic Health. N/A
Completed NCT01435382 - A Pharmacokinetic and Pharmacodynamic Study of PF-04950615 (RN316) in Subjects With Hypercholesterolemia Phase 1
Recruiting NCT02629926 - Transitional Growth Hormone (GH) Use in Growth Hormone Deficient (GHD) Cancer Survivors Phase 4
Completed NCT00707746 - Safety and Efficacy Study of ISIS 301012 (Mipomersen) Administration in High Risk Statin Intolerant Subjects Phase 2
Completed NCT00550706 - Drug Utilization Prevalence in a Pediatric Care Medical Center N/A
Completed NCT03941392 - Nutritional Study in Spanish Pediatric Population
Terminated NCT02440945 - Use of the DBS for the Follow-up of Blood Clinical Parameters of Old People N/A
Not yet recruiting NCT06000605 - Brain Substrate Switch to Ketones and Lactate N/A